Board of Directors:
David Horn, M.D., F.A.C.P., F.I.D.S.A. Chairman:
Dr. Horn brings over 30 years of research expertise in infectious diseases and is board-certified in internal medicine and infectious diseases. Prior to founding Mid-Atlantic Biotherapeutics, Dr. Horn held senior positions in Medical Services and Clinical Development at Merck & Co., Inc., and Professional Services and Medical Affairs at Bristol-Myers Squibb. Dr. Horn has also provided specialty consultancy services to many of the leading pharmaceutical companies. Dr. Horn has designed and performed Phase I-IV clinical trials, and serves on various technology assessment committees. Dr. Horn is board-certified in Internal Medicine and Infectious Diseases, and a fellow of both the American College of Physicians, and the Infectious Disease Society of America. He has authored or co-authored publications concerning HIV infection and AIDS, fungal diseases, bacterial infections, tuberculosis, medical informatics and sepsis.
Dave Jobes, Ph.D.
Dr. Jobes brings over 20 years of research and business development expertise in virology and HIV. Dr. Jobes received his Ph.D. in cell and molecular biology from Tulane University. After completing his postdoctoral training at the NIH, Dr. Jobes worked at Applied Biosystems, where he was integrally involved in bringing a novel HIV drug resistance kit to market, ViroSeq®. He then moved to VaxGen where he ran a research group that characterized the HIV strains isolated from VaxGen’s two international Phase 3 HIV vaccine trials. This work has resulted in numerous publications studying the effects of the vaccines in MSMs and IV drug users. Prior to founding Mid-atlantic Biotherapeutics, David was a co-founder of Presidio Pharmaceuticals, a small molecule HIV and HCV therapeutic company, whose lead compound is now in Phase 1 clinical trials.
Jean-Pierre Gagnon, Ed.D.
Dr. Gagnon has over 35 years of executive experience in U.S. and International Sales & Marketing, Commercial (P&L) Operations (including President – Merck Mexico). During his career at Merck, Dr. Gagnon was the architect for the launches of several multi-billion dollar brands in the US and led large commercial organizations in Canada, US and Latin America. Dr. Gagnon led the launches and the commercialization of the most successful vaccines and anti-infective brands created by Merck over the last 25 years. In 2013, he graduated with a doctoral degree in Global Business Leadership from the University of Pennsylvania (in collaboration with the Wharton Business School and Thunderbird University). Over the years, Dr. Gagnon has developed an extensive global network of thought leaders, business leaders, human and animal health experts, practitioners, and academicians.
Michael Goldblatt, Ph.D.
Michael Goldblatt, was Chief Executive Officer of Functional Genetics, a biotechnology company, until 2013 when its assets were acquired by Elanco, its collaboration partner. Michael joined Functional Genetics in 2003, after his appointment as Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA). Part of Michael’s DARPA responsibilities included creating the foundational efforts to make biology a future historical strength for the Department of Defense by leveraging biology to enhance defense systems and human performance enhancement. Prior to his work with the Department of Defense, Dr. Goldblatt was the Science and Technology Officer for the McDonald’s Corporation with broad responsibilities, including nutrition, product development, food safety and corporate venture capital.
In addition to a variety of public service activities, Michael serves on the boards of a number of aspiring technology and venture startups and maintains membership in the Washington DC and U.S. Patent Bars. Michael received his J.D. and Ph.D. from the University of California at Davis and a B.A. from Reed College.
Julian Chick, Ph.D.
Julian Chick is an experienced corporate executive with over 12 years of experience in senior management roles including Chief Operating Office, Chief Executive Officer, Head of Business Development as well as board positions across the biotechnology and healthcare industries. Dr. Chick has extensive experience running early and late stage research & development projects across a range of therapeutic areas as well as medical devices as well as corporate, operational and business development activities. In various roles Dr. Chick has raised hundreds of millions for R&D projects from global markets. Prior to the executive roles Julian had five years’ experience in stockbroking and investment banking with Prudential-Bache Securities, BNP Paribas and Salomon Smith Barney. He was also the principal analyst with Foursight Associates reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists. Julian has a Ph.D. in Physiology and is currently the COO at Admedus Ltd.